Acute amphetamine (AMPH) exposure elevates extracellular dopamine through a variety of mechanisms that include inhibition of dopamine reuptake, depletion of vesicular stores, and facilitation of dopamine efflux across the plasma membrane. Recent work has shown that the DAT substrate AMPH, unlike cocaine and other nontransported blockers, can also stimulate endocytosis of the plasma membrane dopamine transporter (DAT). Here, we show that when AMPH enters the cytoplasm it rapidly stimulates DAT internalization through a dynamin-dependent, clathrin-independent process. This effect, which can be observed in transfected cells, cultured dopamine neurons, and midbrain slices, is mediated by activation of the small GTPase RhoA. Inhibition of RhoA activity with C3 exotoxin or a dominant-negative RhoA blocks AMPHinduced DAT internalization. These actions depend on AMPH entry into the cell and are blocked by the DAT inhibitor cocaine. AMPH also stimulates cAMP accumulation and PKA-dependent inactivation of RhoA, thus providing a mechanism whereby PKA-and RhoA-dependent signaling pathways can interact to regulate the timing and robustness of AMPH's effects on DAT internalization. Consistent with this model, the activation of D1/D5 receptors that couple to PKA in dopamine neurons antagonizes RhoA activation, DAT internalization, and hyperlocomotion observed in mice after AMPH treatment. These observations support the existence of an unanticipated intracellular target that mediates the effects of AMPH on RhoA and cAMP signaling and suggest new pathways to target to disrupt AMPH action.
B
oth cocaine and amphetamine (AMPH) are psychostimulants that induce euphoria and hyperactivity by increasing extracellular dopamine. Despite the apparent commonalities in the effects and mechanism of action of the two drugs, amphetamine exposure has behavioral, neuroadaptive, and neurotoxic consequences not associated with cocaine use (1) (2) (3) (4) (5) . These dissimilarities likely stem from several differences in the mechanism of action of the two drugs. Amphetamines, unlike cocaine and other nontransported inhibitors of the dopamine transporter (DAT), are transporter substrates that compete with dopamine for transport, enter dopamine neurons, enhance efflux of dopamine, and also stimulate internalization of the DAT from the cell surface (6, 7) . To better understand how amphetamines mediate their effects within the cell, we undertook a series of studies to establish the cellular pathways and signaling mechanisms that underlie the endocytosis of the DAT triggered by amphetamines.
AMPH-mediated DAT internalization has been shown to be dynamin-dependent (6) . Dynamin-dependence is a key feature of clathrin-mediated endocytosis, and, indeed, previous reports of clathrin-dependent constitutive cycling (8) and PKC-mediated internalization (9) of DAT make it reasonable to consider that the same machinery would be involved in AMPH-mediated internalization. A secondary pathway of dynamin-mediated internalization of membrane-localized proteins involves small GTPases of the Rho family. Rho proteins are composed of three subfamilies (Rho, Rac, and CDC42), each of which play a major role in actin cytoskeletal reorganization and vesicular trafficking (10) . To further characterize the dynamin-dependent mechanism of DAT internalization in response to AMPH, we examined if it was mediated by clathrin or whether it was a Rho-dependent process.
We also sought to resolve which signaling pathways activated by AMPH trigger internalization, whether these effects reflect a direct intracellular action of AMPH, and whether they depend on the elevation of extracellular dopamine.
Here, we demonstrate that AMPH [(+)-α-methyl phenylethylamine] acts within the cytoplasm to stimulate Rho family GTPases and trigger DAT internalization through a Rho-and dynamindependent pathway that does not involve clathrin. We also show
Significance
The dopamine transporter (DAT), a major target for psychostimulant drugs, including cocaine and amphetamines, clears extracellular dopamine and restricts the temporal and spatial extent of neurotransmitter signaling. This study examines the mechanism through which amphetamines trigger internalization of DAT and demonstrates that amphetamine activates the small GTPases, Rho and Rac. Rho activation triggers endocytosis of DAT by a dynamin-dependent, clathrin-independent pathway. Intriguingly, amphetamine must enter the cell to have these effects, and it also increases cAMP, which in turn inactivates Rho and limits carrier internalization. Consistent with these observations, the activation of receptors that couple to protein kinase A in dopamine neurons also antagonizes the behavioral effects of amphetamine in mice, suggesting new pathways to target to disrupt amphetamine action.
that cytoplasmic AMPH stimulates a secondary pathway of cAMP production, which leads to Rho inactivation by PKA-dependent phosphorylation. This transient period of Rho activation correlates with ongoing DAT internalization, and this temporal window of activation can be shortened by stimulating cell-surface Gscoupled receptors to raise cAMP and increase the rate of Rho inactivation. We also show in vivo that preemptive D1/D5 receptor stimulation to activate PKA can reduce AMPH-evoked hyperlocomotion without altering the increase in locomotion induced by cocaine. Because these signaling events occur in transfected cell lines as well as in neurons, the results indicate that, once AMPH enters the cell, it activates Rho, Rac, and PKA signaling independently of any actions to elevate intracellular dopamine. The direct activation of cytoplasmic signaling cascades by AMPH within the cell can contribute to the behavioral effects of acute amphetamine exposure and may explain some of the unique neurobiological consequences associated with amphetamine use and abuse.
Results AMPH-Induced DAT Internalization Is Clathrin-Independent. Previous studies have indicated that the endocytosis of DAT activated by AMPH exposure is dynamin-dependent (6); however, the clathrin dependence of this process has been established only for constitutive DAT internalization (8) . Confocal examination of a monoaminergic neuroblastoma line, SK-N-SH, expressing GFPtagged clathrin-light chain (GFP-CLC) and an mCherry-conjugated DAT (mCherry-DAT) after AMPH treatment does not show marked colocalization of the two proteins (Fig. 1A) . Further analyses of AMPH-treated SK-N-SH cells using live-cell total internal reflection fluorescence (TIRF) microscopy demonstrate that less than 0.5% of internalizing DAT colocalizes with clathrin (Movie S1). In contrast, parallel experiments monitoring transferrin accumulation confirm previous studies that over 80% of internalizing transferrin colocalizes with clathrin (Fig. 1B) . Thus, AMPH-stimulated DAT internalization in SK-N-SH cells is dynamin-dependent, but clathrin-independent.
Dynamin-dependent, clathrin-independent internalization is generally divided into two categories depending on whether Rho activation is required (11) . Coexpression of the DAT with a plasmid encoding GFP-tagged C3 exotoxin, a clostridial enzyme that ADP ribosylates and inactivates Rho family GTPases, prevents AMPHinduced clustering and internalization of DAT in SK-N-SH cells ( Fig. 1 C-E and Movie S2). Using TIRF microscopy we observed that expression of C3 for 18-24 h in SK-N-SH cells reduces the number of focal adhesions, consistent with Rho inhibition. The continuing spontaneous movement of the C3(+) cells and their ability to transport dopamine (Fig. 1F) indicate that the cells are still viable. The presence of the Rho inhibitor prevented the increase in DAT endocytosis observed with AMPH, supporting a role for Rho-GTPases in DAT internalization.
Expression of a dominant-negative RhoA (T19N) also inhibits the effects of AMPH on dopamine uptake (Fig. 1F) , and DAT cell-surface expression by TIRF microscopy ( Fig. S1 ), an observation that further confirms the significance of Rho activation to AMPH-stimulated DAT trafficking. Expression of either the C3 or the Rho (T19N) mutant did not alter baseline DAT activity, suggesting that RhoA activation does not play a role in constitutive cycling of the DAT. In addition, the effects of AMPH Fig. 1 . AMPH-induced DAT internalization is clathrin-independent but Rho-dependent. (A) SK-N-SH cells were cotransfected with mCherry-DAT and a clathrin light chain-GFP fusion protein and stimulated with AMPH for 5 min. AMPH causes DAT (red) to internalize but, once endocytosed, DAT fails to colocalize with clathrin (green). (B) SK-N-SH cells were transfected with a GFP-clathrin light chain and treated with transferrin conjugated to Alexa-Fluor-568 for 5 min. These cells exhibit colocalization of clathrin with the transferrin-bound receptors. (C) SK-N-SH cells were cotransfected with mCherry-DAT (green) and GFP-C3 (red; note that pseudocoloring has been reversed for consistency throughout the figures). The field shown here is of a cell expressing DAT and C3 (yellow) and a cell expressing DAT alone (green) at T = 0 (Movie S2). In the absence of C3 coexpression, AMPH causes robust clustering and internalization of DAT at T = 15 and loss of surface DAT by T = 30 (Right, Top). However, AMPH fails to alter DAT at either T = 15 or T = 30 in a cell coexpressing C3 with DAT (Right, Bottom). are mimicked by expression of a constitutively active RhoA (V14) (Fig. 1F) . Rho family GTPases regulate internalization by controlling rearrangement of the actin cytoskeleton and activation of critical enzymes such as phospholipase D (12, 13) . AMPH-induced DAT internalization is sensitive to inhibitors of actin dynamics (latrunculin A and jasplakinolide) (Fig. S2A ) and phospholipase D2 (dominant-negative PLD2 isoform) (Fig. S2B) , and it thus resembles other Rho-mediated internalization processes.
To directly assess the activation of Rho family members by AMPH, active (GTP-bound) Rho and Rac were affinity-purified from SK-N-SH cell lysates using GST-tagged constructs derived from the Rho-binding domain of rhotekin (GST-RBD) and the GTPase-binding motif of p21-activated kinase 1 (GST-PAK1). These constructs selectively bind the activated forms of Rho and Rac, respectively (14, 15) . The bound activated GTPases were identified on immunoblots using specific antibodies to Rho or The ratio of surface GFP-AP-DAT (Alexa Fluor 568) to total GFP-AP-DAT (GFP) in TH(+) neurons is normalized to vehicle control. AMPH (10 μM) treatment reduces surface DAT by 58 ± 6%, and this effect is blocked by 100 μM cocaine. (E) Bar graph showing dopamine uptake in control primary midbrain cultures with either vehicle control or the Rho inhibitor exotoxin C3 introduced into the cells by the scrape method (12) . Approximately 18 h after the neurons were scrapeloaded in the presence or absence of the C3 exotoxin, neuronal cultures were treated with AMPH for 30 min. AMPH significantly decreases dopamine transport in the sham-treated control cultures but has no effect on the cells treated with C3. (F) The ROCK inhibitor Y27632 also attenuates the AMPHinduced decrease in [ 3 H]-dopamine uptake in primary cultures. (G) Primary midbrain neurons expressing GFP-AP-DAT labeled with streptavidin-conjugated gold particles. Transmission electron micrographs of AMPH-stimulated neurons reveal gold particles (arrowhead) in tubulovesicular bodies (TV) and multivesicular bodies (MVB, Inset). Gold particles are absent from clathrin-coated pits or vesicles (CCV). (Scale bars: 50 μm in C, 100 nm in G, and 75 nm in the Inset of G). *P < 0.05, ***P < 0.001, two-way ANOVA.
Rac1. As shown in Fig. 1G , AMPH stimulates activation of both of these GTPases in a time-dependent fashion.
AMPH-Mediated DAT Internalization in Neurons. To determine whether a mechanism involving Rho-dependent endocytosis operates in dopamine neurons, we examined the effect of AMPH pretreatment on transport of radiolabeled dopamine into primary cultures of midbrain neurons. AMPH pretreatment caused a timedependent down-regulation of endogenous DAT activity ( Fig.  2A) . The decrease in dopamine transport activity after 30 min of 10 μM AMPH pretreatment could be prevented by coapplication of the nontransported inhibitor, cocaine, which blocks transport of AMPH into the cells (Fig. 2B) . Pretreatment with cocaine alone under the same conditions had no effect on transport activity (Materials and Methods). Taken together, these results are consistent with the idea that the AMPH acts on an intracellular target to mediate its effects on DAT trafficking (7).
To confirm that the decrease in transport activity reflects a loss of membrane-localized DAT, we engineered a bicistronic plasmid that expresses DAT with a 15-amino-acid biotin ligase acceptor peptide (AP) sequence (16) substituted in the second extracellular loop of DAT (residues 193-203; GFP-AP-DAT) and the Escherichia coli BirA biotin ligase with an endoplasmic reticulum retention signal (BirA-KDEL). We have shown that BirA-KDEL biotinylates the AP tag of the nascent membrane proteins efficiently and selectively within the lumen of the ER before they are trafficked to the surface (17) . This biotinylated DAT can be labeled at the surface with streptavidin conjugated to fluorescent dyes (Fig. 2C) . The presence of the biotinylated AP tag did not significantly alter the ability of the carrier to transport dopamine. In GFP-AP-DAT-transfected primary midbrain neurons, AMPH treatment reduces the proportion of DAT on the surface ( Fig. 2 C and D) . Cocaine alone does not stimulate DAT internalization and yet blocks AMPH-mediated internalization (Fig. 2D) .
To further corroborate that AMPH acts within the cytoplasm through a mechanism that does not depend on its ability to elevate extracellular dopamine, we cotransfected HEK293 cells, which neither synthesize nor release dopamine, with GFP-AP-DAT and the norepinephrine transporter, NET. Because NET transports AMPH with high affinity, these experiments allowed us to test directly whether transport through DAT is specifically necessary for the actions of AMPH. Blocking AMPH transport through DAT with GBR12909 had no effect on AMPH-mediated Rho activation and internalization of DAT, nor did blocking AMPH transport only through NET with desipramine ( Fig. S3 A-C). However, blocking AMPH cytosolic access entirely by coapplication of GBR12909 and desipramine prevented AMPH's effects on Rho activation and DAT surface expression. Similarly, blocking both NET and DAT with cocaine also prevented AMPHmediated DAT internalization. These data support previous observations (7) that AMPH must enter the cell to exert an effect on transporter trafficking; however, the means by which AMPH enters the cell, either directly through DAT or by another route (e.g., NET), does not appear crucial.
To examine the role of Rho activation in AMPH-mediated DAT modulation in primary neurons, we again used the C3 clostridial toxin to inhibit Rho activity; however, because primary neurons are difficult to transfect efficiently with a plasmid expressing the toxin (as in Fig. 1F ), we used a scrape-loading assay (12) to introduce the toxin itself into the cells. Parallel assays with the cell-impermeable fluorophore calcein confirmed the efficient uptake of the C3 ribosyl transferase enzyme using this method. The presence of the C3 toxin prevented the decrease in dopamine uptake mediated by AMPH in primary neuronal cultures, but not in sham-treated control cultures, which indicates that DAT internalization in these cells also depends on the activation of Rho GTPases (Fig. 2E) .
To further confirm the role of Rho activation on AMPHmediated DAT internalization in primary neurons, we investigated a potential downstream effector of Rho activation. The Rho-associated coiled-coil containing kinase (ROCK) is activated by Rho GTPases and plays a critical role in actin cytoskeletal rearrangements. Coapplication of the ROCK inhibitor, Y27632, blocked the effects of AMPH pretreatment on dopamine uptake in primary midbrain cultures (Fig. 2F ). These data further support a role for Rho activation in the mechanism of action of AMPH.
We were also able to use the GFP-AP-DAT system to investigate DAT trafficking ultrastructurally using electron microscopy (EM). In a representative experiment shown in Fig. 2G , we labeled surface GFP-AP-DAT with gold-conjugated streptavidin in cultured midbrain neurons. Ten minutes after AMPH treatment, gold particles were observed on the inner leaflet of cytoplasmic, irregularly shaped, single membrane structures 80-100 nm in width (TV, Fig. 2G ). These structures are consistent with tubulovesicular bodies, which are a hallmark of clathrinindependent internalization (11) . Intriguingly, in immuno-EM studies of midbrain sections, DAT has been observed to be localized not only on the surface, but also prominently in cytoplasmic tubulovesicles (18) . Constitutive DAT internalization has been characterized as a clathrin-mediated process (8) . However, we did not find gold particles in clathrin-coated pits or clathrin-coated vesicles (CCV), suggesting that constitutive internalization is low relative to AMPH-induced internalization under these conditions. AMPH Activates Rho Family GTPases in Acute Brain Slices. Although the localization of GFP-AP-DAT in tubulovesicular bodies supports a role for Rho activation in mediating the effects of AMPH on DAT trafficking in neurons, it was important to confirm that AMPH could activate Rho in the adult mouse brain. We measured endogenous Rho, Rac, and CDC42 activation in response to AMPH in acute midbrain slices and observed activation of both Rho and Rac, but not CDC42 as early as 5 min after AMPH addition ( Fig. 3 A and B) . The precise anatomical localization of activated Rho was determined in acute brain sections by staining with biotinylated GST-RBD. In AMPH-treated sections, there was a clear region of GST-RBD staining that overlapped with tyrosine hydroxylase (TH)-positive neurons of the substantia nigra (Fig. 3C) . Intriguingly, rhotekin binding was observed predominantly in neuronal processes and varicosities and not in the cell bodies, suggesting that Rho activation is spatially regulated within dopaminergic neurons (Fig. 3D) .
AMPH-Induced Increases in cAMP Lead to Rho Inactivation and
Termination of DAT Internalization. The activation of Rho by AMPH is rapid but transient, peaking within 5-10 min in cells, neurons, and tissue (Figs. 1F and 3 A and B) . Because AMPH increases cAMP production (19) , and because it has been shown that PKA negatively regulates RhoA by phosphorylation of a serine residue, S188 (20, 21) , we hypothesized that AMPH-mediated activation of PKA pathways could also serve as brake on Rho signaling. Fig. 4A shows the time course of cAMP accumulation in SK-N-SH cells after AMPH treatment. Peak phosphorylation of RhoA at S188 occurs after the initial Rho activation and, as predicted by the role of S188 phosphorylation in Rho inactivation, parallels the time course of inactivation of Rho (Fig. 4B) . These data suggest that the activation of RhoA by AMPH is terminated by AMPH-mediated activation of PKA.
To verify that Rho phosphorylation by PKA terminates the DAT internalization, SK-N-SH cells were transfected with a construct encoding a mutant RhoA (S188A) that cannot be phosphorylated by PKA (22) . In these cells, AMPH treatment induced significantly more DAT internalization, confirming that phosphorylation of RhoA by PKA terminates RhoA-mediated internalization ( Fig. 4C and Fig. S1 ). Taken together, these observations suggest that AMPH signaling involves a wave of RhoA activation that initiates DAT internalization followed by a wave of PKA-mediated inactivation of RhoA that terminates the endocytic process (Fig. 4F) .
This model predicts that the magnitude of DAT internalization depends on the balance of RhoA activation and PKAdependent RhoA inactivation. Pharmacological manipulation of PKA activity should shift this equilibrium and alter the amount of DAT internalization. Consistent with this idea, pretreatment of SK-N-SH cells with dibutyryl-cAMP (db-cAMP), a PKA agonist, blocks AMPH-induced DAT internalization, whereas pretreatment with KT5720, a PKA inhibitor, enhances the effects of AMPH on the DAT (Fig. 4D) . Using the GFP-AP-DAT/ BirA construct, we also confirmed that modulation of PKA activity alters AMPH-mediated DAT internalization similarly in primary TH-positive midbrain neurons (Fig. 4E) . Moreover, experiments using a radiolabeled cocaine analog, [
125 I]RTI-55, to identify surface carriers in acute brain sections also confirmed that increases in PKA activity decrease AMPH-mediated DAT internalization, whereas PKA inhibitors enhance the effects of AMPH (Fig. S4 A and B) . Taken together, these observations fit with the model presented in Fig. 4F . Although the precise mechanism by which AMPH stimulates Rho and cAMP signaling is unknown, our data indicate that AMPH acts on an intracellular target (or targets) to produce these effects.
Endogenous G Protein-Coupled receptors Modulate AMPH's Effects on DAT Internalization and Locomotor Behavior. cAMP concentrations in dopaminergic neurons are modulated by multiple G protein-coupled receptors (GPCRs). SK-N-SH cells also express many of the GPCRs found in dopamine neurons, and we used this system as a model for how activation of endogenous receptors might integrate PKA-signaling pathways with the actions of AMPH on Rho signaling and DAT internalization. In these studies, we observed that stimulation of the G s -coupled D1/D5 dopamine receptors or the β2 adrenergic receptor, both which are known to increase cAMP, are sufficient to block AMPHinduced DAT internalization as measured by dopamine uptake (Fig. 5A) . We also tried to enhance Rho activation and DAT internalization by stimulating two G i -coupled receptors, the D2 dopamine receptor or the α2-adrenergic receptor, but these manipulations failed to modulate DAT internalization. Finally, stimulation of G q -coupled muscarinic or endothelin 1 receptors, which do not directly affect adenyl cyclase, had no effect on DAT internalization. The D1/D5-selective agonist SKF38393 also blocks the internalization of GFP-AP-DAT in primary dopamine neurons (Fig. 5B) . Furthermore, in midbrain slices we found that AMPHinduced Rho activation could also be prevented by stimulation of D1/D5 G s -coupled receptors by preapplication of SKF38393 (Fig. 5 C and D) . These data suggest that the acute in vivo actions of AMPH might be mitigated by stimulating G s -coupled receptors expressed on midbrain dopamine neurons.
The ability of D1/D5 agonists to modulate AMPH-induced Rho activation, and DAT internalization provides a useful tool to investigate these signaling cascades in vivo. Adult male Swiss-Webster mice that received i.p. injections of AMPH (2 mg/kg) showed a decrease in surface DAT in midbrain slice preparations as measured by biotinylation (Fig. 6A) 6B) . As in primary neurons, SKF38393 blocked DAT internalization (Fig. 6B) . The ability of SKF38393 to block AMPH-mediated DAT internalization was paralleled by the blunting effect of In contrast, inhibition of PKA with 600 nM KT5720 enhances DAT internalization. (E) In primary neurons, the actions of db-cAMP and KT5720 parallel the results seen in SK-N-SH cells as assessed by membrane labeling of the GFP-AP-DAT protein (F) A schematic illustrating the crosstalk between AMPH-induced Rho activation and cAMP signaling. AMPH activates Rho but also stimulates cAMP production, which in turn activates PKA to terminate Rho activation and DAT internalization. *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA; #P < 0.01 compared with RhoA + AMPH in C. (Fig. 6 C and  D) . Mice treated with SKF38393 in the absence of drug exhibit qualitatively similar movement patterns to those injected with vehicle (Fig. 6C) . Importantly, SKF38393 did not inhibit the locomotor effects of cocaine, which demonstrates that this concentration of the D1/D5 agonist did not have a global effect on psychostimulant-induced hyperlocomotion. Taken together, these findings suggest that regulated DAT internalization contributes significantly to the locomotor effects of AMPH.
SKF38393 on AMPH-induced hyperlocomotion

Discussion
Unlike cocaine and other nonsubstrate DAT blockers, amphetamines have the capacity to enter neurons and stimulate endocytosis of the DAT and other surface membrane proteins. To learn more about the cellular signaling pathways activated by intracellular AMPH, we focused on the mechanism of AMPHmediated DAT internalization, a process that intriguingly has been shown to be disrupted in DAT variants associated with ADHD (23) and autism (24) . We show in the work presented here that cytoplasmic AMPH transiently activates Rho family GTPases, which stimulate DAT internalization via a clathrinindependent mechanism. Cytoplasmic AMPH also stimulates cAMP accumulation and increases PKA activity, which feeds back to phosphorylate and inactivate Rho.
Modulation of cAMP and PKA by pharmacological inhibitors or endogenous ligands of Gs-coupled receptors alters AMPHinduced DAT internalization in a manner consistent with a negative feedback loop in which PKA activation limits Rho-mediated internalization. This integration of Rho and PKA-signaling cascades provides a mechanism through which dopamine neurons can dynamically regulate plasma-membrane molecules in response to both intracellular and extracellular signals. The timing and relative activation of each pathway determines the net effect of Rho activation on trafficking of DAT and other potential targets. As a consequence of reduced DAT surface expression, an increase in dopamine receptor activation could further modify the cascades initiated by AMPH. Taken together our data illuminate a series of previously unidentified actions of AMPH on intracellular signaling pathways that are not mimicked by nontransportable DAT blockers, such as cocaine.
AMPH Activated Rho, Rac, and PKA. To examine the possible behavioral consequences of these events, we stimulated D1/D5 receptors with SKF38393 before AMPH treatment to inhibit Rho activation and were able to block the effects of AMPHinduced hyperlocomotion as well as DAT surface expression. Consistent with this model, D5 knockout mice display enhanced locomotor activity in response to methamphetamine (25) . However, our data also suggest that there is a component of psychostimulantinduced hyperlocomotion that is not Rho-mediated because the activation of D1/D5 receptors does not bring the AMPHinduced hyperlocomotion down to control levels, but rather to the level produced by cocaine. It is important to note that, in addition to its effects on Rho-mediated transporter trafficking, AMPH has the potential to elevate extracellular dopamine through other mechanisms, such as facilitating efflux and inhibiting the carriers. Thus, it will be critical to establish which of the various effects predominates at different times after AMPH administration to understand the contribution of each of the different mechanisms to the effects of AMPH in vivo.
The effects of AMPH on intracellular signaling suggests a physiological role of endogenous AMPH-like ligands, which could initiate Rho and PKA activation within dopamine neurons. A number of endogenous amine compounds such as β-phenylethylamine have been proposed as potential "endogenous amphetamines" (26) . However, another plausible physiological Rho activator could be dopamine itself; consistent with this idea, we have preliminary data demonstrating that cytoplasmic dopamine can indeed activate Rho.
The complex downstream effects of Rho-family GTPase-signaling pathways on cellular functions such as actin remodeling and membrane protein trafficking may explain some of the distinct features of the brain's response to AMPH compared with cocaine. For example, the activation of Rho modulates the actin cytoskeleton and neurite extension (27) , both of which have been linked to the plasticity and alterations in dendritic spine morphology observed in models of addiction (28) . Our data using a ROCK inhibitor to block the effects of AMPH pretreatment on dopamine uptake link ROCK activation to DAT internalization, complementing previous studies that suggest a role for ROCK in some aspects of AMPH's behavioral effects (29) . AMPH treatment also stimulates Rac, which influences neurite extension and branching and oxidative stress-induced cell death (30) . Furthermore, the potential transcriptional consequences of AMPH's ability to increase cAMP and activate CREB signaling in the nucleus is also likely to contribute to longer-term adaptive changes in dopamine neurons that would not be seen with cocaine.
Here we focused on the actions of AMPH on RhoA-dependent internalization of the DAT and explored how these effects on DAT trafficking might contribute to the acute behavioral response to the drug. However, recently we also demonstrated that a neuronal glutamate transporter, EAAT3, can be internalized in response to AMPH through a process that also appears to require Rho activation (17) . This EAAT3 internalization in response to AMPH leads to a potentiation of glutamatergic synaptic responses in dopamine neurons and reveals a previously undescribed action of AMPH on glutamatergic signaling. A recent study has shown striking compartmentalization of glutamatergic and dopaminergic release sites within the processes of TH-positive neurons, where the two vesicular transporter types, VMAT2 and VGluT2, are segregated within distinct subcompartments (31) . Intriguingly, we observe Rho activation broadly distributed within the processes of dopamine neurons. Taken together, these findings suggest a complex integration of dopaminergic and glutamatergic transmission within the mesoaccumbens pathway.
Cytoplasmic Target(s) of AMPH. The activation of intracellular signaling pathways by AMPH and the Rho-mediated internalization of DAT are also observed in nonneural cell lines transfected with DAT, which demonstrates that these effects do not require synaptic vesicles or endogenous dopamine. We also found that the presence of AMPH within the cytosol, and not the binding and transport through DAT, was essential for stimulating these signaling cascades; AMPH transport through NET could support Rho activation and trigger internalization of coexpressed DAT. This observation is consistent with a previous report showing that a DAT mutant incapable of AMPH transport could be internalized when AMPH was directly applied intracellularly via a whole-cell patch pipette (7) .
The precise nature and the pharmacological properties of the cytoplasmic target(s) of AMPH remain to be established, but a trace amine-associated receptor, TAAR1, that is expressed in Pretreatment with SKF38393 significantly decreases AMPH-induced ambulation, but it does not affect cocaine-induced activity or have a significant effect on its own **P < 0.0001 by paired t test; *P < 0.05, two-way ANOVA.
dopamine neurons and has a predominantly intracellular distribution is a potential candidate. As a Gs-coupled GPCR that responds to a variety of endogenous and exogenous amines and neurotransmitter metabolites, TAAR1 has been shown to be activated by AMPH and a variety of AMPH-like compounds and is likely responsible for the increases in cAMP generally observed following the application of AMPH to cells (32, 33) . Whether TAAR1 also mediates the activation of the small GTPases, RhoA, and Rac1 remains to be established.
Together, the studies reported here indicate that the effects of AMPH not only depend on the drug's well-established actions on uptake and efflux through the DAT, but also require the activation of multiple signaling pathways by acting on additional target(s) within the cell. Cytoplasmic cAMP appears to integrate both intracellular signals through GTPase activation and extracellular signals from GPCR-coupled pathways to shape response of a dopamine neuron to AMPH. Thus, modulation of the Rho activation/inactivation sequence provides a mechanism by which drugs and endogenous neurotransmitters can influence the response of dopamine neurons to AMPH. Microscopy. The cells were kept at 37°C using an Open Perfusion MicroIncubator (Harvard Apparatus) and imaged using an Olympus Fluoview 1000 confocal microscope equipped with a SIM scanner. TIRF images were acquired with an Olympus 1 × 71 equipped with a 60× TIRF objective or an A1 Nikon confocal with a 100× TIRF objective. Images were acquired at 10-s intervals for 1-2 min before addition of treatments. Fluorescence intensity data of the whole cell or of specific regions of interest were exported to Prism6 and analyzed by fitting to a single exponential decay. GFP-AP-DAT Labeling. Drug treatments were applied to transfected cells for 30 min at 37°C in MEM. Cells were washed and chilled to 4°C to minimize further trafficking events. Surface GFP-AP-DAT was labeled with streptavidinconjugated Alexa Fluor-568 in 5% (wt/vol) milk for 20 min, rinsed, and fixed with 4% (wt/vol) paraformaldehyde (PFA). Cells were immunolabeled for TH(+) with an Alexa Fluor-647 secondary antibody. TH(+)/GFP(+) cells were identified, and GFP and Alexa Fluor-568 fluorescence intensities were measured with the photon-counting module of Fluoview software. Membrane expression was determined as a ratio of Alexa Fluor-568/GFP fluorescence, normalized to vehicle-treated controls. Baseline GFP fluorescence indicated no significant effect on overall expression of the CMV-promoter-driven constructs.
Materials and Methods
Acute Brain Slices. Brains from naive or IP-injected adult male Swiss-Webster mice (Charles River) were removed and sectioned coronally into 1-mm slices in cold HBSS. Midbrain slices were allowed to recover for 60 min at room temperature in artificial CSF (aCSF, in mM: 126 NaCl, 3. Rho GTPase Activation. GST-conjugated Rho and Rac/CDC42-binding domains of Rhotekin and p21-activated kinase (PAK1), respectively, were purified from E. coli and bound to glutathione-Sepharose beads (14, 15) . Acute brain slices or transiently transfected cells were treated with vehicle or AMPH. Lysates were prepared in binding buffer [50 mM Tris·Cl, pH 7.2, 1% (vol/vol) Triton X-100, 500 mM NaCl, 10 mM MgCl 2 ]. Activated Rho proteins were captured overnight at 4°C. The beads were washed, and the protein was eluted with Laemmli's buffer containing 200 mM DTT, separated on SDS gels, transferred to Immobilon filters, and probed with antibodies to Rho, Rac, or CDC42. Both activated Rac and CDC42 bind to the GST-PAK1 fusion protein, and the two GTPases are differentiated by the primary antibodies used to examine them by Western blot. Secondary HRP antibodies were used to detect the proteins, activated with Western Lightening Plus ECL chemiluminescence and imaged on a Chem Doc-It Imaging System. Samples taken before GST-fusion purification were used to assess equal protein loading. Data were quantitated with Image J.
Activated Rho Staining of Acute Brain Slices. GST-RBD and GST were purified on a glutathione column, biotinylated with EZ-Link NHS-Biotin, 1 mg/mL, and dialyzed in PBS. Acute brain-slice cells were prepared and treated with AMPH and snap-frozen in isopentene. Ten-micrometer sections were made from this tissue, blocked, permeablized with 4% (wt/vol) BSA/1% (vol/vol) Triton X-100, and labeled with the biotinylated GST or GST-RBD. Sections were then washed and fixed with 4% (wt/vol) PFA. Endogenous peroxidase was quenched, and streptavidin-HRP was bound to the biotinylated GST complex and developed with a DAB reaction.
Biotinylation of Midbrain Slices. Cell-surface biotinylation was performed as described previously (17) based on the methods of Daniels and Amara (37) . Briefly, 39 min after IP of AMPH, 2 mg/kg, male Swiss-Webster mice were killed and their brains were removed. One-millimeter coronal slices of the midbrain were made and rapidly chilled in ice-cold HBSS for 30 min. Cellsurface proteins were biotinylated with the cell-impermeable reagent 2 mg/mL sulfosuccinimidyl 2-(biotinamido) methyl-1,3-dithiopropionate (sulfo-NHS-SS-biotin) (Pierce) in biotinylation buffer (in mM: 2 CaCl2, 150 NaCl, and 10 triethanolamine, pH 7.5) for 30 min. The biotin reagent was quenched with a 20-min glycine wash (100 mM in PBS). The tissue was homogenized in lysis buffer [1% (vol/vol) Triton X-100, 150 mM NaCl, 5 mM EDTA, and 50 mM Tris, pH 7.5, containing a protease inhibitor mixture (Roche Molecular Biochemicals)]. Biotinylated proteins were extracted by an overnight incubation with Ultralink immobilized NeutrAvidin beads (Pierce) at 4°C. The beads were washed with a high-salt wash buffer (0.1% Triton X-100, 500 mM NaCl, 5 mM EDTA, and 50 mM Tris, pH 7.5) followed by a no-salt wash buffer (50 mM Tris, pH 7.5). Proteins were analyzed by Western blot. Input samples that were set aside before Neutravidin isolation were also analyzed to assure equal loading of proteins as well as to assess for potential degradation of proteins by these procedures. Intracellular proteins were not biotin-labeled as assessed by an absence of actin staining in the biotinylated fractions.
Behavioral Assessment. The behavioral tests were conducted in the Rodent Behavior Analysis Core of the University of Pittsburgh Schools of Health Sciences. Adult male Swiss-Webster mice were maintained on a 12/12 h lightdark cycle with ad libitum access to food and water. Mice were handled daily during the light phase for 5 consecutive days. The next day, individual mice were placed into an arena (25 cm × 25 cm × 30 cm) fitted with infrared light beams and detectors for tracking of movement in the horizontal plane (Coulbourn Instruments). Each arena was housed in a sound-attenuating chamber with ambient illumination level of ∼18 lx. After 30 min, mice were injected IP with physiological saline (vehicle solution; 3 mL/kg) or SKF38393 (3 mg/kg) followed 5 min later with AMPH (2 mg/kg) or cocaine (20 mg/kg). Mice were returned to the test arenas, and their activity was monitored for an additional 60 min.
Statistical Analysis. All data presented as mean and SEM unless otherwise noted. Statistical significance was calculated with Prism 6 software, typically by two-way ANOVA with Bonferroni posttest or one-way ANOVA with Tukey posttest unless otherwise noted (*P < 0.05, **P < 0.01, ***P < 0.001).
Drugs and Reagents. All drugs were from Sigma unless otherwise noted. Antibodies used in this study were from Abcam (Rho, ab40673; RAC1+RAC2, ab68828; CDC42, ab41429; Rho-S188p, ab41435; Sigma TH, T2928) or Chemicon (DAT, MAB369). Secondary antibodies were from Jackson Immunoresearch (HRP conjugates) or Life Technologies (Alexa-Fluor reagents).
